Table 1.
Patient Baseline Characteristics.
| Placebo (N=20) | Dupilumab (N=40) | |
|---|---|---|
| Mean age, years (SD) | 46.5 (14.4) | 41.6 (13.8) |
| Female sex | 13 (65%) | 30 (75%) |
| Race | ||
| White | 15 (75%) | 31 (77.5%) |
| African American | 2 (10%) | 3 (7.5%) |
| Asian | 2 (10%) | 6 (15%) |
| Other | 1 (5%) | 0 (0%) |
| Mean duration since last hair regrowth, years (SD) | 3.5 (3) | 3.8 (2.9) |
| Mean SALT (SD) | 75.4 (26.1) | 70.5 (27.6) |
| Patients with SALT≥75 | 12 (60%) | 20 (50%) |
| Patients with SALT<75 | 8 (40%) | 20 (50%) |
| Patients with Alopecia Totalis/Universalis | 8 (40%) | 13 (32.5%) |
| Mean AASSIS score (SD) | 56.1 (33.8) | 48.4 (30.7) |
| Mean AA-QLI score (SD) | 51.8 (14.2) | 49.5 (12.7) |
| Mean eyelash assessment (0–4 scale) (SD) | 2 (1.6) | 2.07 (1.57) |
| Mean eyebrow assessment (0–4 scale) (SD) | 1.8 (1.54) | 1.9 (1.53) |
| Patients with AD history | 6 (30%) | 17 (42.5%) |
| Patients with active AD | 2 (10%) | 5 (12.5%) |
| Mean EASI score (SD) | 27.4 (15.6) | 13.6 (6.4) |
| Patients with family history of atopy | 9 (45%) | 18 (45%) |
| Mean IgE, IU/ml (SD) | 342.5 (826.7) | 525.8 (1211.3) |
| Patients with IgE≥200 IU/ml | 5 (25%) | 13 (32.5%) |
AASIS, denoted alopecia areata symptom impact scale, AA-QLI, alopecia areata quality of life index, AD, atopic dermatitis, EASI, eczema area and severity index, SALT, severity of alopecia tool, and SD, standard deviation.